NRX Pharmaceuticals, Inc. Q4 FY2024 earnings call

Jonathan Javitt mentioned that over the past five months, the company raised new capital, retired toxic debt, and shifted from a purely research and development-focused company to a healthcare company aiming to generate revenue and profit by the end of 2025. NeuroRx initiated the filing of an NDA for NRX-100 (preservative-free intravenous ketamine) with manufacturing capacity to supply over 1 million doses per month if approved, and is preparing an accelerated NDA filing for NRX-101. HOPE Therapeutics was created, focused on delivering clinical care, and has signed non-binding letters of intent to acquire profitable psychiatry clinics. Michael Abrams reviewed the financial results, noting the decrease in research and development and general administrative expenses, and the company's cash position as of December 31, 2024, and in January 2025.

For the year ended December 31, 2024, NRx Pharmaceuticals reduced its loss from operations by approximately $9.3 million, or 33.5%, to $18.5 million, down from $27.8 million in 2023. Research and development expense decreased by approximately $7.2 million or 53.6% to $6.2 million in 2024, primarily due to the conclusion of the Phase 2b/3 study for NRX-101. General administrative expense decreased by approximately $7.7 million to $13.5 million in 2024. As of December 31, 2024, the company had approximately $1.4 million in cash and cash equivalents. In January 2025, the company completed two financings with aggregate gross proceeds of approximately $8.5 million. Management believes the current available cash resources will be sufficient to support ongoing operations through at least the end of 2025.

Management believes the current available cash resources will be sufficient to support ongoing operations through at least the end of 2025. NRx continues to implement operational efficiencies to extend cash runway and maintain focus on generating revenue and value for shareholders.

Challenges include the toxic preservative in the old ketamine formulation, which can cause issues like skin ulcers and inconsistent blood levels; also, risks associated with acquiring psychiatry clinics such as legal and regulatory due diligence complexities.

Q: How does removing the preservative from ketamine change the formulation?

A: The preservative was originally for multi-use vials. Single-use vials don't need preservatives. We have preservative-free ketamine with 2-year room temperature shelf stability, similar to how the ophthalmology industry moved to single-dose preservative-free vials.

Q: Talk about acquisition strategy for clinics and ANDA/NDA?

A: Acquisitions of clinics are expected to be chunky. The NDA for NRX-100 is to add depression and suicidality indications to the ketamine label. The ANDA is for a preservative-free version of generic ketamine, using the same manufacturing package as the NDA.

Q: Thoughts on international market for approvals?

A: Discussed relationships in France and interest from Asia-Pacific; expect interest to increase as momentum builds for the company's products.

Q: How does HOPE benefit NRx shareholders?

A: HOPE is an asset on NRx's balance sheet. Profits from HOPE will benefit NRx shareholders, and there's potential for a spin-out of HOPE shares to NRx shareholders in a tax-free manner.